Consumer healthcare and weak euro spare Sanofi-Aventis blushes
This article was originally published in Scrip
Executive Summary
Sanofi-Aventis' consumer healthcare and generics businesses helped spare any blushes as the French pharma giant reported its annual results for 2010. Overall, sales declined by just under 1% to €30.4 billion with more than €2 billion of sales, notably of Lovenox (enoxaparin) in the US, were lost through generic competition. The weak euro was also a big contributor to shoring up Sanofi-Aventis' financials.